Amylyx Pharmaceuticals, Inc.
AMLX
Ранг среди акций
#4246
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Цена акции
$29.32
Последняя синхронизация: 2026-10-21
Рыночная капитализация
$3.68B
Изменение (1 день)
1.91%
Изменение (1 год)
97.84%
Страна
US
Торговля Amylyx Pharmaceuticals, Inc. (AMLX)
Категория
Healthcare
История цены акций Amylyx Pharmaceuticals, Inc. (AMLX)
Наивысшая цена закрытия: $27.68 2026-10-01
Наименьшая цена закрытия: $19.75 2022-01-01
Наименьшая цена закрытия: $19.75 2022-01-01
История цены акций Amylyx Pharmaceuticals, Inc. с 2022 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | 41.29% |
| 2025 | 192.53% |
| 2024 | -69.40% |
| 2023 | -60.37% |
| 2022 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
